Velesco is involved in providing analytical method development, drug formulation, stability testing and consulting services.

Rubicon CEO James Koziarz said Velesco provides the company an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of its diagnostic kits ramp up.

"We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business," Koziarz added.

Rubicon has recently signed a supply agreement with Agendia, a molecular diagnostics firm for its TransPLEX whole genome RNA amplification technology.

Agendia is using Rubicon’s kits to facilitate the analysis of formalin-fixed, paraffin-embedded (FFPE) patient samples for use with its Symphony breast cancer diagnostics.